China's NMPA accepts Legend Biotech's NDA for cilta-cel - Pharmaceutical Business review
Cilta-cel is a BCMA-directed and genetically modified autologous T-cell immunotherapy that involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR), which detects